S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
NASDAQ:OYST

Oyster Point Pharma (OYST) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$11.17
$11.17
50-Day Range
$11.08
$11.20
52-Week Range
$3.46
$19.00
Volume
330 shs
Average Volume
212,171 shs
Market Capitalization
$299.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
OYST stock logo

About Oyster Point Pharma Stock (NASDAQ:OYST)

Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

OYST Stock News Headlines

The 25 Best Restaurants in Boston Right Now
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Q4 2023 Viatris Inc Earnings Call
Oyster River School Board candidate John Colwell
Oyster Point Pharma Inc.
What Is Oyster Pie?
Oyster roast helps further land trust mission
See More Headlines
Receive OYST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oyster Point Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
4/18/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:OYST
Fax
N/A
Employees
303
Year Founded
N/A

Profitability

Net Income
$-100,660,000.00
Net Margins
-901.99%
Pretax Margin
-901.99%

Debt

Sales & Book Value

Annual Sales
$24.54 million
Book Value
$3.80 per share

Miscellaneous

Free Float
22,039,000
Market Cap
$299.85 million
Optionable
Not Optionable
Beta
1.31
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Jeffrey Nau MMS (Age 47)
    Ph.D., Pres, CEO & Director
    Comp: $962.85k
  • Mr. Daniel Lochner M.B.A. (Age 40)
    CFO & Chief Bus. Officer
    Comp: $642k
  • Mr. George Donato M.B.A.
    Sr. VP of CMC & Operations
  • Dr. Eric Carlson Ph.D.
    Chief Scientific Officer
  • Arty Ahmed
    VP of Investor relations
  • Mr. Barry Rosenfeld J.D.
    Sr. VP & Gen. Counsel
  • Ms. Raegan A. McClain CCEP
    J.D., L.L.M., Chief Compliance & Privacy Officer
  • Ms. Karen Castillo-Paff
    VP of Communications & PR
  • Mr. Dave Benadon
    Chief HR Officer
  • Ms. Loni Da Silva M.S.
    Sr. VP of Regulatory Affairs

OYST Stock Analysis - Frequently Asked Questions

How were Oyster Point Pharma's earnings last quarter?

Oyster Point Pharma, Inc. (NASDAQ:OYST) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.48. The business earned $17.94 million during the quarter. Oyster Point Pharma had a negative net margin of 901.99% and a negative trailing twelve-month return on equity of 490.33%. During the same quarter last year, the company posted ($0.63) EPS.

What other stocks do shareholders of Oyster Point Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oyster Point Pharma investors own include OPKO Health (OPK), Pfizer (PFE), Akero Therapeutics (AKRO), Walt Disney (DIS), Energy Transfer (ET), Fulcrum Therapeutics (FULC), Johnson & Johnson (JNJ), Occidental Petroleum (OXY) and vTv Therapeutics (VTVT).

When did Oyster Point Pharma IPO?

Oyster Point Pharma (OYST) raised $85 million in an IPO on Thursday, October 31st 2019. The company issued 5,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Cowen and Piper Jaffray served as the underwriters for the IPO.

This page (NASDAQ:OYST) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners